

LICENSURE:

Diplomate, National Board Medical Examiner	7/1/94
State of New Jersey	7/8/94
State of Florida	9/1/66

PROFESSIONAL AFFILIATIONS:

Chairman, Medical and Scientific Committee, Florida State Chapter, Arthritis Foundation	1977-1980
Board of Directors, Professional Standard Review Organization, Broward/Collier Counties	1979
Executive Committee Broward and Collier Professional Standards Review Organization	1980
Delegate/Member, Patient Care Committee, National Arthritis Foundation	1980-1981
President, Florida Society of Rheumatology	1980-1982
Member, Medical Advisory Committee Dade/Broward Lupus Foundation	1983-Present
President, Association of South Broward Physicians, Inc. Memorial Hospital Staff	1984-1986
Fellow, American College of Rheumatology	1986-Present

Fellow, American College of Physician 1978-Present

Representative-at-Large Member 1987-1992
Executive Committee, Broward
County Medical Association

Delegate for Broward County, 1987-1992
Florida Medical Association

MEDICAL SCHOOL AFFILIATION:

Clinical Assistant Professor of 1987-Present
Medicine, Arthritis Section,
University of Miami School of Medicine

HOSPITAL APPOINTMENTS:

Chief Department of Medicine, 1978-1980
Hollywood Medical Center
Hollywood, Florida

Chief of Staff 1980-1982
Hollywood Medical Center

Secretary/Treasurer 1983-1984
Medical Staff Memorial Hospital
Hollywood Florida

Vice-President 1984-1985
Medical Staff Memorial Hospital
Hollywood, Florida

Chief of Staff 1985-1987
Memorial Hospital
Hollywood, Florida

Chairman of the Board 1987-1989
Memorial Health System
Broward, Inc.

Chief of Staff Memorial Hospital West Pembroke Pines, Florida	1991-Present
---	--------------

AWARDS:

Arthritis Foundation, National Volunteer Service Citation	1973
--	------

MEMBERSHIP IN MEDICAL ASSOCIATIONS:

American Medical Association

Broward County Medical Association Secretary	1990-1991
---	-----------

Florida Medical Association	1995-present
-----------------------------	--------------

Voluntary Reviewer in Rheumatology
State of Florida Board of Medicine

RESEARCH STUDIES:

Effectiveness of Tolectin in the treatment of rheumatoid arthritis, McNell, 1973.

Effectiveness of Pirprofen in the treatment of rheumatoid arthritis, Ciba-Geigy, 1974.

Fenbufen in comparison with Placebo in patients with classical and definite rheumatoid arthritis, Lederie, 1977-1980.

Effectiveness of Oxaprozin in the treatment of degenerative joint disease, Wyeth 1979.

Levamisole rheumatoid arthritis study, Janssen R&D, Inc., 1979.

Isoxicam/buffered Aspirin double-blind study in the treatment of patients with active rheumatoid arthritis. Warner Lambert, 1980-1983.

Auranofin/Placebo with NSAID double-blind study in the treatment of patients with active rheumatoid arthritis. SKF, 1980-1982.

Double-blind study, comparing efficacy and safety of Tiflamizole (EN 350) with Placebo in osteoarthritis. Endo Laboratories, (Subsidiary of E.I. Du Pont de Nemours & Co., Inc.), 1982-1983.

Four-week, double-blind, randomized parallel long-term comparison of Naproxen 375 m.g., b.i.d. with Naproxen 750 m.g., b.i.d. in patients with rheumatoid arthritis. Syntex Laboratories, 1982-1983.

Double-blind, multi-center, controlled study of the efficacy and tolerability of Clinoril 300 mg. twice a day versus Clinoril 200 mgs. twice a day in the treatment of rheumatoid arthritis. Merck Sharp & Dohme Research Laboratories, 1983.

Open multicentric evaluation of the safety and efficacy of Tiflamizole (EN 350) in the long-term treatment of patients with osteoarthritis of the hip or knee. Endo Laboratories, Inc, (subsidiary of E.I. Du Pont de Nemours & Co., Inc.), 1983-1985.

Six-week, double-blind, controlled, randomized, parallel study to compare the efficacy and safety of 1000 MG Nabumetone to Placebo in the treatment of degenerative joint disease (Osteoarthritis). Beecham Laboratories, 1984-1985.

Twelve-month, open-label controlled evaluation of Nabumetone in the treatment of active osteoarthritis in adult patients. Beecham Laboratories, 1984-1988.

A Phase II, double-blind, multi-center study comparing the safety and efficacy of two dosing regimens of Tiflamizole in patients with rheumatoid arthritis. E.I. Du Pont de Nemours & Co., Inc., 1984-1985.

Charles B. Kahn, M.D., FACP, FACR

RESEARCH STUDIES:

Page 2

Comparative efficacy and safety of Disalcid and aspirin in rheumatoid arthritis patients. Riker Laboratories Inc., 1985-1986.

Open-label study of marketed NSAID treatment in patients with osteoarthritis using the Arthritis Impact Measurement Scales. Ciba Geigy, 1986-1988.

Open-label study of Voltaren treatment in patients with Osteoarthritis, Ciba Geigy, 1986-1988.

Phase III, double-blind study comparing the safety and efficacy of two doses of Azapropazone with Indomethacin in the treatment of acute gout. E.I. Du Pont de Nemours & Co., Inc., 1986.

Phase III, multi-center, double-blind study comparing the safety and efficacy of Azapropazone with Allopurinol in the management of chronic gout. E.I. Du Pont de Nemours & Co., Inc., 1986.

Multi-site, double-blind, parallel group comparison of Therafectin and Placebo as adjunctive therapy in patients with rheumatoid arthritis. Greenwich Pharmaceutical, 1986-1987.

Efficacy and safety study of daily oral administration of Tilomisol in patients with active rheumatoid arthritis. Wyeth Laboratories, 1986.

Long-term open label safety and efficacy study for patients completing "A multi-site, double-blind, parallel group comparison of Therafectin and Placebo as adjunctive therapy in patients with rheumatoid arthritis." Greenwich Pharmaceutical, Inc., 1987-1988.

Open-label study of Voltaren treatment in patients with rheumatoid arthritis, Ciba Geigy, 1987-1988.

Open-label study of marketed NSAID treatment in patients with rheumatoid arthritis. Ciba Geigy, 1987-1988.

Double-blind, randomized study of Therafectin (Amiprilose HCL) 6 grams/day, compared to Placebo in patients with rheumatoid arthritis withdrawn from their non-steroidal anti-inflammatory drug therapy (RA9 and RA10). Greenwich, Pharmaceutical, Inc. 1987-1988.

Charles B. Kahn, M.D., FACP, FACR

RESEARCH STUDIES:

Page 3

Sonotron Device Study--Osteoarthritis of the knee. ADM Tronics, 1988.

Open-label extension study of Therafectin (Amiprilose HCL) 6 grams/day in patients completing RA9.

Open-label extension study of Therafectin (Amiprilose HCL) 6 grams/day in patients completing RA10.

Six-week, multiple-dose safety and efficacy comparison of Naproxen multi-particulate C 1000 MG tablets to Naproxen standard tablets in patients with arthritis followed by Open-label treatment with multi-particulate C tablets alone. Syntex Laboratories, 1989.

Randomized, double-blind withdrawal of Therafectin (Amiprilose HCL), followed by a 52 week open-label extension study in rheumatoid arthritic patients. (RA11). Greenwich Pharmaceutical, Inc. 1989.

Four-week Placebo controlled comparison of the efficacy and safety of orally administered Etodolac and Diclofenac in patients with degenerative joint disease of the knee, followed by a 12-week, double-blind comparison of Etodolac and Diclofenac. Wyeth Ayerst Research, 1989-1990.

Comparison of the efficacy and safety of orally administered Etodolac and Piroxicam in patients with active rheumatoid arthritis. Wyeth Ayerst Research, 1989-1990.

Efficacy, safety, and tolerability evaluation of Diclofenac sodium vs. Naproxen in the treatment of rheumatoid arthritis. Ciba Geigy, 1989-1990.

Nine-month, double-blind, Placebo controlled multiple dose efficacy and safety study of RS 61443-000 in patients with rheumatoid arthritis. Syntex Research, 1990.

Four-week single-blind efficacy and safety study of Feldene versus Voltaren in the treatment of patients with rheumatoid arthritis. Pfizer Laboratories, 1990.

A 104 week open-label use study of background anti-rheumatic therapy and rescue medication in patients treated with Therafectin (RA 11W). Greenwich Pharmaceutical, Inc. 1990.

One-year, open-label, multiple dose efficacy and safety extension study of RS 61443-000 in patients with rheumatoid arthritis. Syntex research. 1991-1992.

Double-blind, randomized, placebo-controlled study of Therafectin (Amiprilose HCL) in rheumatoid arthritis patients concomitantly treated and then withdrawn from non-steroidal anti-inflammatory drug therapy (RA 12), Greenwich Pharmaceutical, 1992.

Charles B. Kahn, M.D., FACP, FACR

RESEARCH STUDIES:

Page 4

Nine-month, double-blind, multiple dose efficacy and safety comparison of Mycophenolate Mofetil, 2 gms. daily versus 4 gms. daily in rheumatoid arthritis patients. Syntex research 1992.

Double-blind comparison of Nabumetone and Indomethacin in the treatment of moderate to severe osteoarthritis patients as outpatients. SmithKline Beecham, 1992.

Fifty-six week, double blind comparison of the safety and efficacy of Bromfenac and Ibuprofen in patients with active osteoarthritis of the hip or knee with Placebo control during the first four weeks. Wyeth/Ayerst Research, 1992.

A multicenter, randomized, double-blind, placebo-controlled parallel group study to determine the efficacy and safety of Risedronate in the treatment of Osteoporosis in elderly woman. Proctor and Gamble, 1994-Present

Searle--Double-Blind, Placebo-Controlled, Randomized Comparison Study of the Efficacy and Safety of Two Doses of SC-58635 BID and Naproxen 500 mg. BID in Treating the Signs and Symptoms of Rheumatoid Arthritis 1996-present.

Searle--Clinical Protocol to Evaluate the Long-Term Safety of SC-58635 in Treating the Signs and Symptoms of Osteoarthritis and Rheumatoid Arthritis 1996-present.

Roche--A Double-Blind, Randomized, Parallel Group, Multicentre Comparison of the Efficacy and Safety of Mycophenolate Mofetil (MMF-RS61443) PO (1 g BID) and Placebo in Patients with Active Rheumatoid Arthritis (6-Month Efficacy Study) Who are Candidates for Immunosuppressive Therapy of RA 1997-present.

Millennium Pharmaceuticals, Inc.--Rheumatoid arthritis genetic Epidemiology study 1997-study.

HYAL Pharmaceutical Corporation--A multicentre, double-blind, placebo-controlled, parallel group clinical study to evaluate the efficacy and safety of topical 3% Diclofenac gel (HYANALGESE-D) in the treatment of pain associated with osteoarthritis of the knee. 1997-present.

BIBLIOGRAPHY

Kahn, CB, Hollander, JL, and Schumacher, HR: Corticosteroid Crystals in Synovial Fluid. J.A.M.A., 211:807, 1970.

Kahn, CB: Charcot-Leyden or Corticosteroid Crystals? Arthritis and Rheumatism, Vol. 25, #9, p. 1148, September 1982 (Letter to the Editor).

Kahn, CB, Riskin WG: Routine Laboratory monitoring with Non-Steroidal Anti-inflammatory Drugs. J. Florida Med. Assn., Vol.70 #10 October 1983.

Kolodny, AL, Klipper, AR, Harrison, BK, Howard, FM, Kahn, CB, Riskin, WG, Weaver, AL, Wilkens, R: The Efficacy and Safety of Single Daily Doses of Oxaprozin in the Treatment of Osteoarthritis. A comparison with Aspirin. Seminars in Arthritis and Rheumatology., Vol XV, #3, suppl. 2, February 1986.